Federation des caisses Desjardins du Quebec’s Protalix BioTherapeutics PLX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$543	Hold	250	–	–	﹤0.01%	2812
2025 Q4	$450	Hold	250	–	–	﹤0.01%	2743
2025 Q3	$555	Hold	250	–	–	﹤0.01%	2723
2025 Q2	$370	Hold	250	–	–	﹤0.01%	2599
2025 Q1	$640	Hold	250	–	–	﹤0.01%	2466
2024 Q4	$470	Hold	250	–	–	﹤0.01%	2391
2024 Q3	$255	Hold	250	–	–	﹤0.01%	2447
2024 Q2	$293	Hold	250	–	–	﹤0.01%	2306
2024 Q1	$315	Hold	250	–	–	﹤0.01%	2278
2023 Q4	$445	Sell	250 -175	-41%	-$272	﹤0.01%	2208
2023 Q3	$706	Buy	425 +175	+70%	+$314	﹤0.01%	2183
2023 Q2	$500	Hold	250	–	–	﹤0.01%	2193
2023 Q1	$525	Hold	250	–	–	﹤0.01%	2208
2022 Q4	$343	Hold	250	–	–	﹤0.01%	2374
2022 Q3	$260	Hold	250	–	–	﹤0.01%	2434
2022 Q2	$273	Sell	250 -850	-77%	-$994	﹤0.01%	2474
2022 Q1	$1.17K	Hold	1,100	–	–	﹤0.01%	2416
2021 Q4	$915	Hold	1,100	–	–	﹤0.01%	2423
2021 Q3	$1.46K	Hold	1,100	–	–	﹤0.01%	2430
2021 Q2	$2.1K	Hold	1,100	–	–	﹤0.01%	2383
2021 Q1	$4.91K	Hold	1,100	–	–	﹤0.01%	2199
2020 Q4	$3.99K	Hold	1,100	–	–	﹤0.01%	2128
2020 Q3	$4.26K	Hold	1,100	–	–	﹤0.01%	1888
2020 Q2	$4.17K	Hold	1,100	–	–	﹤0.01%	1844
2020 Q1	$2.58K	Hold	1,100	–	–	﹤0.01%	1959
2019 Q4	$3.61K	Hold	1,100	–	–	﹤0.01%	2077
2019 Q3	$2.25K	Hold	1,100	–	–	﹤0.01%	2078
2019 Q2	$5.16K	Hold	1,100	–	–	﹤0.01%	1984
2019 Q1	$4.84K	Hold	1,100	–	–	﹤0.01%	1814
2018 Q4	$3.42K	Hold	1,100	–	–	﹤0.01%	1839
2018 Q3	$8K	Hold	1,100	–	–	﹤0.01%	1775
2018 Q2	$4.73K	Hold	1,100	–	–	﹤0.01%	1905
2018 Q1	$5.94K	Buy	1,100 +850	+340%	+$5.59K	﹤0.01%	1832
2017 Q4	$1.65K	Hold	250	–	–	﹤0.01%	2011
2017 Q3	$1.45K	Hold	250	–	–	﹤0.01%	1966
2017 Q2	$2.1K	Hold	250	–	–	﹤0.01%	2004
2017 Q1	$3.4K	Buy	+250	New	+$2.25K	﹤0.01%	1598

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's PLX Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 250 shares worth $543. The position accounts for ﹤0.01% of the portfolio, ranked #2812.

Federation des caisses Desjardins du Quebec first reported a position in PLX in Q1 2017 and has held it in 37 quarters since. The position peaked at $8K in Q3 2018. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Federation des caisses Desjardins du Quebec held 250 shares of Protalix BioTherapeutics worth $543 as of Q1 2026.
Federation des caisses Desjardins du Quebec left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2812 holding.
Federation des caisses Desjardins du Quebec first reported a position in Protalix BioTherapeutics in Q1 2017 and has held it in 37 quarters since.
Federation des caisses Desjardins du Quebec's Protalix BioTherapeutics position peaked at $8K in Q3 2018.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.